BlueSphere Bio names board chair
Pittsburgh biotech firm BlueSphere Bio has named industry vet Jonathan Peacock as its board chair.
BlueSphere Bio is developing T-cell therapies for leukemia and is also working on therapies for solid tumors. The firm recently finished a $105 million Series B round that was led by UPMC Enterprises.
Peacock is the former CFO of Amgen and is lead director of Avantor and is also a board member of Genmab and UCB. BlueSphere Bio said that Peacock and other moves will help the company build up its…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Paul J. Gough Source Type: news